Abdulrazak Alchakaki, MD
Critical Care Medicine · Southfield, MINPI 1407088123
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,543 of the $19,471 with a category attached, or 69.6%. Regeneron Healthcare Solutions, Inc. accounts for 84.5% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $14,426, more than ten times the $78 reported in 2019. Among critical care medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $189.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$16K
- GSK$1K
- Intuitive Surgical$705
- Sanofi$283
- AstraZeneca$252
- Boehringer Ingelheim$123
- plus $495 from 10 others
What the payments were for
- Consulting fees$2,44813%
- Speaking & faculty fees$13,54370%
- Travel & lodging$7974%
- Food & beverage$2,40712%
- Education$2761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 16 | $16,461 |
| GSK | 54 | $1,152 |
| Intuitive Surgical | 4 | $705 |
| Sanofi | 6 | $283 |
| AstraZeneca | 3 | $252 |
| Boehringer Ingelheim | 3 | $123 |
| Insmed, Inc. | 5 | $101 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $87 |
| Advanced Respiratory, Inc | 2 | $42 |
| Mylan Specialty L.p. | 2 | $42 |
| Pulmonx Corporation | 2 | $33 |
| Harmony Biosciences LLC | 1 | $32 |
| Baxter Healthcare | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$16,374
- Da Vinci Surgical System$686
- AREXVY$245
- TEZSPIRE$237
- NUCALA$124
How this compares
$19,471 in reported general payments places this provider in the 95th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 339 | $307,572 |
| Dupixent PenDupilumab | 31 | $125,153 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $63,840 |
| NucalaMepolizumab | 13 | $45,564 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $39,052 |
| Spiriva RespimatTiotropium Bromide | 44 | $26,508 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $18,536 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,231 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,294 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $5,527 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,828 |
| Ventolin HfaAlbuterol Sulfate | 23 | $2,032 |
| Azithromycin | 51 | $683 |
| Prednisone | 78 | $275 |
| Bumetanide | 12 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta | $1,152 | $432,206464 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $123 | $65,560102 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $252 | $25,83046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Southfield
- Dhananjay ShirgaviSouthfield$849
- Angel Peralta-AvilaDetroit$147K
- Moumen AsbahiTroy$81K
- Mujahed AbbasLansing$28K
- Narayana GandhamSaint Joseph$18K
- Sara MirzaAnn Arbor$12K
- Asker AsmiRiverview$11K
- Andrew EasowDearborn$10K
- Jeffery WiltGrand Rapids$10K
- Furqan SiddiqiSaint Joseph$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.